Cipla's US Arm Secures Exclusive Licensing Deal for QL2107 Biosimilar

Cipla's US arm, InvaGen Pharmaceuticals, has partnered with Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar referencing Merck's blockbuster cancer drug Keytruda (pembrolizumab), in the United States.

Under this agreement, Qilu will manage product development and supply, while Cipla will lead commercialization efforts in the US market using its existing infrastructure. This collaboration expands Cipla's presence in the complex biologics and oncology segment, a key strategic growth area alongside its traditional respiratory and complex generics portfolio.

The reference biologic drug Keytruda recorded quarterly sales of $8.4 billion for Merck, positioning this deal as a major long-term revenue opportunity for Cipla.